Literature DB >> 11238946

beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter.

S Hapke1, M Gawaz, K Dehne, J Köhler, J F Marshall, H Graeff, M Schmitt, U Reuning, E Lengyel.   

Abstract

Migration of cells requires interactions with the extracellular matrix mediated, in part, by integrins, proteases, and their receptors. Previous studies have shown that beta(3)-integrin interacts with the urokinase-type plasminogen activator receptor (u-PAR) at the cell surface. Since integrins mediate signaling into the cell, the current study was undertaken to determine if in addition beta(3)-integrin regulates u-PAR expression. Overexpression of beta(3)-integrin in CHO cells, which are avid expressers of the receptor, downregulated u-PAR protein and mRNA expression. The u-PAR promoter (-1,469 bp) that is normally constitutively active in CHO cells was downregulated by induced beta(3)-integrin expression. A region between -398 and -197 bp of the u-PAR promoter was critical for beta(3)-integrin-induced downregulation of u-PAR promoter activity. Deletion of the PEA3/ets motif at -248 bp substantially impaired the ability of beta(3)-integrin to downregulate the u-PAR promoter, suggesting that the PEA3/ets site acts as a silencing element. An expression vector encoding the transcription factor PEA3 caused inhibition of the wild-type but not the PEA3/ets-deleted u-PAR promoter. The PEA3/ets site bound nuclear factors from CHO cells specifically, but binding was enhanced when beta(3)-integrin was overexpressed. A PEA3 antibody inhibited DNA-protein complex formation, indicating the presence of PEA3. Downregulation of the u-PAR promoter was achieved by the beta(3)A-integrin isoform but not by other beta(3)-integrin isoforms and required the cytoplasmic membrane NITY(759) motif. Moreover, overexpression of the short but not the long isoform of the beta(3)-integrin adapter protein beta(3)-endonexin blocked u-PAR promoter activity through the PEA3/ets binding site. Thus, besides the physical interaction of beta(3)-integrin and u-PAR at the cell surface, beta(3) signaling is implicated in the regulation of u-PAR gene transcription, suggesting a mutual regulation of adhesion and proteolysis receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238946      PMCID: PMC86830          DOI: 10.1128/MCB.21.6.2118-2132.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  62 in total

Review 1.  The AP-1 site and MMP gene regulation: what is all the fuss about?

Authors:  U Benbow; C E Brinckerhoff
Journal:  Matrix Biol       Date:  1997-03       Impact factor: 11.583

2.  Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components.

Authors:  W Xue; I Mizukami; R F Todd; H R Petty
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

3.  Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells.

Authors:  S Shetty; A Kumar; S Idell
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

Review 4.  The role of alpha v-integrins in tumour progression and metastasis.

Authors:  J F Marshall; I R Hart
Journal:  Semin Cancer Biol       Date:  1996-06       Impact factor: 15.707

5.  A conserved sequence motif in the integrin beta3 cytoplasmic domain is required for its specific interaction with beta3-endonexin.

Authors:  M Eigenthaler; L Höfferer; S J Shattil; M H Ginsberg
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

6.  Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells.

Authors:  D I Simon; N K Rao; H Xu; Y Wei; O Majdic; E Ronne; L Kobzik; H A Chapman
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

7.  Integrin beta 3 cDNA transfection into a highly metastatic alpha v beta 3-negative human melanoma cell line inhibits invasion and experimental metastasis.

Authors:  E H Danen; A A van Kraats; I M Cornelissen; D J Ruiter; G N van Muijen
Journal:  Biochem Biophys Res Commun       Date:  1996-09-04       Impact factor: 3.575

8.  Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression.

Authors:  J Schneikert; H Peterziel; P A Defossez; H Klocker; Y de Launoit; A C Cato
Journal:  J Biol Chem       Date:  1996-09-27       Impact factor: 5.157

9.  Pointed, an ETS domain transcription factor, negatively regulates the EGF receptor pathway in Drosophila oogenesis.

Authors:  A M Morimoto; K C Jordan; K Tietze; J S Britton; E M O'Neill; H Ruohola-Baker
Journal:  Development       Date:  1996-12       Impact factor: 6.868

10.  Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.

Authors:  J A Aguirre Ghiso; K Kovalski; L Ossowski
Journal:  J Cell Biol       Date:  1999-10-04       Impact factor: 10.539

View more
  10 in total

1.  Collagen binding alpha2beta1 and alpha1beta1 integrins play contrasting roles in regulation of Ets-1 expression in human liver myofibroblasts.

Authors:  Iya Znoyko; Maria Trojanowska; Adrian Reuben
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

2.  ITGB3 shows genetic and expression interaction with SLC6A4.

Authors:  Lauren A Weiss; Carole Ober; Edwin H Cook
Journal:  Hum Genet       Date:  2006-05-24       Impact factor: 4.132

3.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.

Authors:  Ben Davidson; Iris Goldberg; Liora Tell; Sophya Vigdorchik; Mark Baekelandt; Aasmund Berner; Gunnar B Kristensen; Reuven Reich; Juri Kopolovic
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.

Authors:  Hilary A Kenny; Swayamjot Kaur; Lisa M Coussens; Ernst Lengyel
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

5.  Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene.

Authors:  Heng Wang; John Hicks; Parham Khanbolooki; Sun-Jin Kim; Chunhong Yan; Yao Wang; Douglas Boyd
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

6.  Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.

Authors:  Hilary A Kenny; Chun-Yi Chiang; Erin A White; Elizabeth M Schryver; Mohammed Habis; Iris L Romero; Andras Ladanyi; Carla V Penicka; Joshy George; Karl Matlin; Anthony Montag; Kristen Wroblewski; S Diane Yamada; Andrew P Mazar; David Bowtell; Ernst Lengyel
Journal:  J Clin Invest       Date:  2014-09-09       Impact factor: 14.808

7.  {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.

Authors:  Swayamjot Kaur; Hilary A Kenny; Sujatha Jagadeeswaran; Marion R Zillhardt; Anthony G Montag; Emily Kistner; S Diane Yamada; Anirban K Mitra; Ernst Lengyel
Journal:  Am J Pathol       Date:  2009-10-01       Impact factor: 4.307

8.  Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway.

Authors:  Santosh Chauhan; Douglas D Boyd
Journal:  Nucleic Acids Res       Date:  2011-09-21       Impact factor: 16.971

9.  Peptides derived from the integrin β cytoplasmic tails inhibit angiogenesis.

Authors:  Zhongyuan Cao; Xinfeng Suo; Yudan Chu; Zhou Xu; Yun Bao; Chunxiao Miao; Wenfeng Deng; Kaijun Mao; Juan Gao; Zhen Xu; Yan-Qing Ma
Journal:  Cell Commun Signal       Date:  2018-07-03       Impact factor: 5.712

10.  The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.

Authors:  Uffe V Schneider; Rikke L Nielsen; Court Pedersen; Jesper Eugen-Olsen
Journal:  BMC Infect Dis       Date:  2007-11-16       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.